February 28, 2013

Has the explosion in generic utilization curbed pioneer-drug research and development? That's one concern floated by some pharmaceutical industry watchers, who claim that the stunning market share gains made by generic drug makers could reduce incentives for branded drug companies to spend to develop new molecular entities, conduct lengthy clinical trials, gain FDA approval and bring those new drugs to market.

February 28, 2013

The world market for generic drugs will jump more than 15% this year and reach a global total of $127.8 billion, predicted a report from British market research firm Visiongain.

February 25, 2013

The generic drug tidal wave became a tsunami in 2012, with some of the world's top-selling pharmaceuticals swamped by generic competition, and health plan payers scrambling to reap billions of dollars in financial savings.

February 15, 2013

U.S. marshals, acting on behalf of the Food and Drug Administration, on Thursday seized tainted products from Globe All Wellness in Hollywood, Fla.

February 12, 2013

The Colon Cancer Challenge Foundation, a nonprofit organization dedicated to reducing colorectal cancer incidence and death throughout the United States, presented Sanofi with its annual Blue Star Corporate Award.

February 5, 2013

Cardinal Health posted $25.2 billion in revenue for its 2013 second quarter, down 7%. The company's non-GAAP diluted earnings per share was up 15% to $0.93.

February 4, 2013

H. D. Smith announced the appointment of Tim Booth to EVP, Smith Medical Partners. Smith Medical Partners is a wholly owned subsidiary of H. D. Smith focused on specialty pharmaceutical distribution and services, and is part of the newly formed H. D. Smith Specialty Solutions group.

January 31, 2013

The Electronic Retailing Self-Regulation Program determined the National Weight Loss Institute can support general weight-loss claims made in direct-response advertising for Prevoxin, a dietary supplement intended to promote weight loss, but recommended the marketer modify or discontinue certain claims.

January 28, 2013

Health care is evolving. As obvious of a statement as that is, it doesn’t change the fact that it is very real. Throughout last year, there was intense discussion on the Patient Protection and Affordable Care Act and what impact the outcome of the presidential election might have on its future. Now that the Supreme Court has ruled and elections are settled, healthcare companies and providers across the country are implementing strategies to meet ACA requirements.

January 22, 2013

H. D. Smith announced the establishment of H. D. Smith Specialty Solutions, an organization structured to provide focus and alignment around specialty and traditional brand products, solutions and services.

January 16, 2013

The Food and Drug Administration has set user fee rates for generic drug companies, the agency said.

January 15, 2013

H. D. Smith announced plans to secure majority ownership in Triplefin, a privately held reimbursement, patient assistance and pharmaceutical brand support services company headquartered in Cincinnati, Ohio.

January 7, 2013

While pressure to grow will drive more large drug makers to pursue mergers and acquisitions, diminished resources and competition from biotech and specialty pharmaceutical companies will challenge their ability to do so, according to a new report.

January 2, 2013

In 2012, the Food and Drug Administration approved 39 new drugs, 8 alone in December, marking the largest increase in 16 years.

December 28, 2012

Solidifying Perrigo’s leadership position in topical foam-based generic prescription pharmaceuticals, the company announced it has signed a definitive merger agreement and completed the acquisition of Cobrek Pharmaceuticals.

December 11, 2012

E-prescribing offers many well-known benefits to physicians, pharmacists and patients alike. Beyond the well-known patient benefits, real-time transactions with automated requests and responses promise to create efficiencies by speeding the medication ordering process, reducing or eliminating the back-and-forth communications between pharmacists and clinicians commonly associated with handwritten prescriptions.

December 5, 2012

Drug maker Novo Nordisk is creating what it calls the world's first all-diabetes professional cycling team, the company said.

December 3, 2012

Specialty pharmacy purchasing and channel management group Armada Health Care and healthcare services company Amerinet will provide services to each other's members under a co-marketing agreement, the two companies said Monday.

November 29, 2012

Just how much of an impact the loss of patent protection can have on a blockbuster drug became clear earlier this year.


November 29, 2012

Patent settlements between generic and branded drug companies seem like one of the most controversial and long-standing issues in the pharmaceutical world, with strong opinions on both sides.


November 29, 2012

In 2011 and 2012, the steady surge of blockbuster pharmaceuticals falling off the patent cliff became a stampede. An astonishing number of big-selling drugs that had established and sustained branded drug makers’ profits for years fell victim to the expiration of their patent lives and market exclusivity, roiling the pharmaceutical marketplace and redefining the pricing model for many of the most widely prescribed classes of medicines.


November 29, 2012

Generic Pharmaceutical Association president and CEO Ralph Neas called it “the most important pharmaceutical legislation since the 1984 Hatch-Waxman Act.” John Castellani, president and CEO of the Pharmaceutical Research and Manufacturers of America, said the law served “the best interests of America’s patients.”


November 28, 2012

Physicians Interactive and McKesson Patient Relationship Solutions on Tuesday announced a joint collaboration to deliver eCoupon, one of the industry’s first automated pharmaceutical voucher and coupon distribution solution for clinicians who use electronic health records and ePrescribing software.

November 21, 2012

During Fred's third-quarter earnings call, the company told analysts it was testing a new, smaller format drug-dollar store concept and that its partnership with Diplomat was creating new clinical capabilities for the chain, which still sees pharmacy as a major growth opportunity.

The more Memphis-area patients continue singing those Delta blues, the more they're going to be scuffling through Fred's doors in their blue suede shoes. Effectively serving that economically-challenged patient is just one reason why Fred's third-quarter call this week should resonate across the industry. Because Fred's is in pursuit of two trends that are critical to its future — a specialty pharmacy solution that gains Fred's entree into the only growth-game in pharmacy, and an answer to its big-box competitors with a small-footprint, dollar-store/pharmacy hybrid.